LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SCYX
SCYNEXIS, Inc.
There isn't enough reported data to score SCYX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SCYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
SCYX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SCYX PE Valuation
SCYX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SCYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SCYX's losses to grow, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SCYX on earnings quality, reporting a profit while its opponent remains loss making.
SCYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$2.64 |
| Q2 2026 | -$2.09 | +$1.11 |
| Q1 2026 | -$3.84 | +$0.64 |
| Q4 2025 | -$1.36 | +$2.16 |
| Q3 2025 | -$4.08 | +$1.28 |
| Q2 2025 | -$3.20 | +$2.00 |
| Q1 2025 | -$4.48 | -127% |
| Q4 2024 | -$3.52 | -132% |
SCYX is still losing money, but far less than before: $1.44 per share over the past year, against $76.62 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SCYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SCYX on profitability, with a higher operating margin.
SCYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $235K | -83% |
| Q4 2025 | $18.6M | +1808% |
| Q3 2025 | $334K | -49% |
| Q2 2025 | $1.4M | +85% |
| Q1 2025 | $257K | -81% |
| Q4 2024 | $977K | -83% |
| Q3 2024 | $660K | -63% |
| Q2 2024 | $736K | -99% |
SCYX's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3309% | -2608 points |
| Q4 2025 | 56% | +881 points |
| Q3 2025 | -2516% | -953 points |
| Q2 2025 | -701% | +554 points |
| Q1 2025 | -3350% | -2658 points |
| Q4 2024 | -824% | -426 points |
| Q3 2024 | -1564% | -990 points |
| Q2 2024 | -1255% | -1344 points |
SCYX's operating margin was −3309% last quarter, up 42 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SCYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
SCYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5M | +$1.3M |
| Q2 2026 | -$14.9M | -$7.4M |
| Q1 2026 | -$8.1M | -$636K |
| Q4 2025 | $18.4M | +$28.3M |
| Q3 2025 | -$8.7M | -1240% |
| Q2 2025 | -$7.5M | +$3.4M |
| Q1 2025 | -$7.5M | -$3.5M |
| Q4 2024 | -$9.9M | -$2.2M |
SCYX has burned cash in almost every quarter: −$12M over the past year, against −$34M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SCYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SCYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18.8K shares |
| 1 year | +90% | +5.6M shares |
| 3 years | +90% | +5.6M shares |
| 5 years | +257% | +8.5M shares |
SCYX has 12M diluted shares, up 90% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SCYX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.6x | Net Cash |
| Q2 2023 | -0.9x | Net Cash |
SCYX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SCYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 6.3 | Oversold |
SCYX's weekly RSI is 36 (neutral) and its Stochastic is 6 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SCYX PE vs Healthcare Sector
| Metric | SCYX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCYX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SCYX on trend strength, trading above more of its moving averages.
SCYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.96 | 16% below |
| 20 week MA | $4.44 | 25% below |
| 50 week MA | $5.40 | 38% below |
| 100 week MA | $6.29 | 47% below |
| 200 week MA | $11.4 | 71% below |
SCYX is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SCYX on returns for 2026, with the stronger performance.
SCYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.8 | $57.1 | -18% |
| 2021 | $57.1 | $54.0 | -5.5% |
| 2022 | $54.0 | $12.5 | -77% |
| 2023 | $12.5 | $17.8 | +43% |
| 2024 | $17.8 | $7.99 | -55% |
| 2025 | $7.99 | $4.70 | -41% |
| 2026 YTD | $4.70 | $3.33 | -29% |
SCYX has finished lower in five of the last six years. It's down 29% so far in 2026.